Investments
411Portfolio Exits
116Funds
11Partners & Customers
5About SV Health Investors
SV Health Investors is a healthcare and life sciences venture capital and growth equity firm that makes investments in businesses at all stages of development and across the human life sciences sector. The firm targets early-stage opportunities in biotechnology, early-stage and revenue-stage opportunities in medical devices, and growth equity investments for later-stage businesses in healthcare services and digital health. It was founded in 1993 and is based in Boston, Massachusetts.

Want to inform investors similar to SV Health Investors about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing SV Health Investors
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned SV Health Investors in 1 CB Insights research brief, most recently on Sep 2, 2020.
Latest SV Health Investors News
Jan 26, 2023
What You Should Know: – Today, Health Payment Systems, Inc. (HPS) /PayMedix announced it has raised another $25M of funding to accelerate the growth of its PayMedix healthcare financing solution led by SVB Capital with partipcation from existing investors SV Health Investors, Hexagon, Inc. and Caltius Equity. – PayMedix increases health equity for all consumers by guaranteeing full and prompt payments of all in-network allowed charges for participating healthcare providers. All consumers can schedule needed services, and their providers all know that full payment is guaranteed. All consumers at a sponsoring employer receive one simplified summary of all of their healthcare activity and know that PayMedix has served as a financial safety net if they needed one. All of these patients are guaranteed access to PayMedix regardless their credit histories. – To date, PayMedix has already processed more than $5 billion in payments and continues to enhance its financial technology platform to offer a complete solution that serves all parts of the healthcare payment equation.
SV Health Investors Investments
411 Investments
SV Health Investors has made 411 investments. Their latest investment was in Health Payment Systems as part of their Unattributed VC on January 1, 2023.

SV Health Investors Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/25/2023 | Unattributed VC | Health Payment Systems | No | 3 | ||
1/25/2023 | Debt | Health Payment Systems | $25M | Yes | Caltius Equity Partners, Hexagon, SV Health Investors, SVB Capital, and Undisclosed Investors | 5 |
12/28/2022 | Series B | Aro Biotherapeutics | $24.03M | Yes | 1 | |
12/6/2022 | Series C - II | |||||
11/9/2022 | Series A - II |
Date | 1/25/2023 | 1/25/2023 | 12/28/2022 | 12/6/2022 | 11/9/2022 |
---|---|---|---|---|---|
Round | Unattributed VC | Debt | Series B | Series C - II | Series A - II |
Company | Health Payment Systems | Health Payment Systems | Aro Biotherapeutics | ||
Amount | $25M | $24.03M | |||
New? | No | Yes | Yes | ||
Co-Investors | Caltius Equity Partners, Hexagon, SV Health Investors, SVB Capital, and Undisclosed Investors | ||||
Sources | 3 | 5 | 1 |
SV Health Investors Portfolio Exits
116 Portfolio Exits
SV Health Investors has 116 portfolio exits. Their latest portfolio exit was AcuFocus on January 17, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/17/2023 | Acquired | 9 | |||
6/1/2022 | Acquired | 3 | |||
11/24/2021 | IPO | Public | 2 | ||
Date | 1/17/2023 | 6/1/2022 | 11/24/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 9 | 3 | 2 |
SV Health Investors Acquisitions
9 Acquisitions
SV Health Investors acquired 9 companies. Their latest acquisition was Health Payment Systems on February 04, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/4/2021 | Other Venture Capital | $25.68M | Acq - Fin | 2 | ||
11/5/2014 | Debt | |||||
7/15/2011 | ||||||
8/20/2008 | ||||||
7/22/2008 |
Date | 2/4/2021 | 11/5/2014 | 7/15/2011 | 8/20/2008 | 7/22/2008 |
---|---|---|---|---|---|
Investment Stage | Other Venture Capital | Debt | |||
Companies | |||||
Valuation | |||||
Total Funding | $25.68M | ||||
Note | Acq - Fin | ||||
Sources | 2 |
SV Health Investors Fund History
11 Fund Histories
SV Health Investors has 11 funds, including SV Biotech Crossover Opportunities Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
1/16/2023 | SV Biotech Crossover Opportunities Fund | $48.6M | 1 | ||
11/10/2020 | SV7 Growth Fund | $91.31M | 3 | ||
7/20/2020 | SV7 Impact Medicine Fund | $265M | 2 | ||
4/6/2020 | Medtech Convergence Fund | ||||
4/12/2017 | SV Life Sciences Fund VI Strategic Partners |
Closing Date | 1/16/2023 | 11/10/2020 | 7/20/2020 | 4/6/2020 | 4/12/2017 |
---|---|---|---|---|---|
Fund | SV Biotech Crossover Opportunities Fund | SV7 Growth Fund | SV7 Impact Medicine Fund | Medtech Convergence Fund | SV Life Sciences Fund VI Strategic Partners |
Fund Type | |||||
Status | |||||
Amount | $48.6M | $91.31M | $265M | ||
Sources | 1 | 3 | 2 |
SV Health Investors Partners & Customers
5 Partners and customers
SV Health Investors has 5 strategic partners and customers. SV Health Investors recently partnered with Cancer Research UK on July 7, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
7/2/2019 | Partner | United Kingdom | In conjunction with the partnership , Cancer Research UK is investing at least US$ 25 million in SV Health Investors 's seventh biotech-focused venture capital fund , SV7 Impact Medicine Fund , which is expected to raise US$ 250 million . | 3 | |
4/15/2016 | Partner | ||||
4/15/2016 | Partner | ||||
7/10/2008 | Partner | ||||
10/2/2000 | Partner |
Date | 7/2/2019 | 4/15/2016 | 4/15/2016 | 7/10/2008 | 10/2/2000 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United Kingdom | ||||
News Snippet | In conjunction with the partnership , Cancer Research UK is investing at least US$ 25 million in SV Health Investors 's seventh biotech-focused venture capital fund , SV7 Impact Medicine Fund , which is expected to raise US$ 250 million . | ||||
Sources | 3 |
SV Health Investors Team
13 Team Members
SV Health Investors has 13 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Graham Boulnois | Founder | Current | |
Name | Graham Boulnois | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.